^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Jiataile (sacituzumab tirumotecan)

    i
    Other names: SKB-264, MK2870, MK 2870, MK-2870, SKB 264, SKB264, sac-TMT
    Company:
    Merck (MSD), Sichuan Kelun Pharma
    Drug class:
    Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate
    Related drugs:
    1d
    Cost-effectiveness analysis of Sacituzumab Tirumotecan as second-line therapy for EGFR-TKI-resistant, EGFR-Mutated advanced NSCLC in China. (PubMed, Expert Rev Pharmacoecon Outcomes Res)
    This study estimated the cost-effectiveness of sacituzumab tirumotecan (Sac-TMT) versus pemetrexed-platinum chemotherapy as second-line therapy for advanced EGFR-mutated non-small cell lung cancer (NSCLC) in China. A price reduction exceeding 73.81% would bring the ICER below the WTP threshold. At current prices, Sac-TMT is not cost-effective as second-line therapy for advanced EGFR-mutated NSCLC in China.
    Journal • HEOR • Cost-effectiveness
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    pemetrexed • Jiataile (sacituzumab tirumotecan)
    6d
    Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer. (PubMed, Cancer Cell)
    An ongoing phase 2 trial evaluating first-line sac-TMT plus osimertinib combination therapy in patients with advanced EGFR-mutant NSCLC shows preliminary efficacy. Together, our findings establish TROP2 as a therapeutically actionable vulnerability in DTP cells and support the clinical development of TROP2-ADC combined with EGFR-TKI as a first-line strategy to delay TKI resistance and improve outcomes in EGFR-mutant NSCLC.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • Jiataile (sacituzumab tirumotecan)
    12d
    A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) (clinicaltrials.gov)
    P1/2, N=190, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: May 2037 --> Apr 2032
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • patritumab deruxtecan (U3-1402) • Jiataile (sacituzumab tirumotecan) • calderasib (MK-1084)
    14d
    STOP-NEPC: Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior Chemotherapy (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Virginia Commonwealth University
    New P2 trial
    |
    CD4 (CD4 Molecule) • SYP (Synaptophysin)
    |
    Jiataile (sacituzumab tirumotecan)
    18d
    STARTER: Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations (clinicaltrials.gov)
    P3, N=420, Not yet recruiting, Fudan University
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • ER negative
    |
    capecitabine • Jiataile (sacituzumab tirumotecan)
    21d
    Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases (clinicaltrials.gov)
    P2, N=24, Recruiting, Fudan University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative • HER-2 negative + HR negative
    |
    Avastin (bevacizumab) • Jiataile (sacituzumab tirumotecan)
    22d
    Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Jiataile (sacituzumab tirumotecan)
    26d
    Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial. (PubMed, Lancet)
    Among patients with PD-L1-positive advanced NSCLC without targetable genomic alterations, first-line treatment with sac-TMT plus pembrolizumab significantly prolonged progression-free survival compared with pembrolizumab alone. Therefore, sac-TMT plus pembrolizumab has the potential to redefine first-line treatment for patients with PD-L1-positive advanced NSCLC without targetable genomic alterations.
    P3 data • P3 data: top line • Journal
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Jiataile (sacituzumab tirumotecan)
    27d
    A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) (clinicaltrials.gov)
    P3, N=686, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    gemcitabine • pemetrexed • irinotecan • vinorelbine tartrate • topotecan • Jiataile (sacituzumab tirumotecan) • Tivdak (tisotumab vedotin-tftv)
    30d
    Cost-effectiveness analysis based on two models of sacituzumab tirumotecan versus platinum-based chemotherapy as second-line treatment in EGFR-mutant non-small-cell lung cancer. (PubMed, Front Public Health)
    To improve patient access, substantial price reductions or inclusion in the National Reimbursement Drug List are necessary. These findings may inform both clinical decisions and health resource allocation.
    Journal • HEOR • Cost-effectiveness
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Jiataile (sacituzumab tirumotecan)
    1m
    TroFuse-009: Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (clinicaltrials.gov)
    P3, N=520, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    carboplatin • pemetrexed • dexamethasone • Jiataile (sacituzumab tirumotecan)
    1m
    ADC and SBRT for Recurrent/Metastatic Salivary Gland Carcinoma (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    Meiyouheng (becotatug vedotin) • Jiataile (sacituzumab tirumotecan)